Binding Affinity News Today

Group A Streptococcal M-related proteins (Mrps) are dimeric α-helical-coiled-coil cell membrane-bound surface proteins. During infection, Mrp recruit the fragment crystallizable region of human immunoglobulin G via their A-repeat regions to the bacterial surface, conferring upon the bacteria enhanced phagocytosis resistance and augmented growth in human blood. However, Mrps show a high degree of sequence diversity, and it is currently not known whether this diversity affects the Mrp–IgG inter...

Study uncovers how Neisseria gonorrhoeae, a major sexually transmitted infection pathogen, utilizes host-produced hormonal steroids to enhance its drug resistance and survival, revealing a complex interaction between bacterial resistance mechanisms and human hormonal environment.

Scientist explores transformative potential of bispecific antibody-based drug to lay foundation for improved healthcare

Scientist explores transformative potential of bispecific antibody-based drug to lay foundation for improved healthcare

Zentek Reports Successful Testing of Aptamer Against Omicron Covid-19 Variant

Researchers discover the BA.2.86 Omicron lineage with higher transmission potential than current dominant strains, yet show that existing antivirals remain effective. Despite its higher infectivity, BA.2.86 exhibits lower pathogenicity in hamsters, indicating decreased replication capacity may lead to less severe infections.

Researchers at Nagoya University in Japan created and improved artificial intelligence (AI) designs to synthesize a candidate compound for a new gastric acid inhibitor with a better binding affinity than existing drugs.

Researchers examined the antigenicity of the emerging SARS-CoV-2 subvariant BA.2.86, finding that it is not resistant to neutralizing antibodies from previously infected or vaccinated individuals, although it does show increased binding affinity to the ACE-2 receptor. The study highlights the subvariant's sensitivity and resistance to different classes of monoclonal antibodies, offering insights for future treatment and vaccine development.

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the acquisition of BioPharmics LLC.

A hybrid approach involving a combination of conventional discovery and antibody repurposing to combat COVID-19.